Three-Pronged attack on Tough-to-Treat colon cancer
NCT ID NCT07343791
Summary
This early-stage study is testing a new three-part treatment for advanced colorectal cancer that has stopped responding to standard therapies. It combines an immunotherapy drug, a targeted cancer drug, and a personalized cell therapy made from the patient's own immune cells. The main goals are to see if this combination can slow cancer growth and is safe for patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital
RECRUITINGNanjing, Jiangsu, 210002, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.